GSK statement on avodart™ (dutasteride) for prostate cancer risk reduction

Research output: Contribution to journal › Comment/debate › peer-review

ASJC Scopus subject areas

@article{e64798eaad604881937a15287bf3d811,

title = "GSK statement on avodart{\texttrademark} (dutasteride) for prostate cancer risk reduction",

author = "Walsh, \{Patrick C.\}",

year = "2011",

month = aug,

doi = "10.1016/j.juro.2011.04.053",

language = "English (US)",

volume = "186",

pages = "530",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Wolters Kluwer Health",

number = "2",

}

TY - JOUR

T1 - GSK statement on avodart™ (dutasteride) for prostate cancer risk reduction

AU - Walsh, Patrick C.

PY - 2011/8

Y1 - 2011/8

UR - https://www.scopus.com/pages/publications/79960160704

UR - https://www.scopus.com/pages/publications/79960160704#tab=citedBy

U2 - 10.1016/j.juro.2011.04.053

DO - 10.1016/j.juro.2011.04.053

M3 - Comment/debate

AN - SCOPUS:79960160704

SN - 0022-5347

VL - 186

SP - 530

JO - Journal of Urology

JF - Journal of Urology

IS - 2

ER -